View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
February 23, 2022

UK MHRA approves Skymount trial for AI-discovered Covid-19 therapeutics

In cell and animal studies, the two-drug combination showed to decrease SARS-CoV-2 viral load.

Skymount Medical received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to commence a clinical trial of its oral treatments for mild-to-moderate Covid-19. 

The double-blind human trial will analyse the potential impact of a two-drug combination and a single antiviral drug versus placebo on Covid-19 symptom severity and duration.

Discovered using the Louisiana State University (LSU)-developed DeepDrug artificial intelligence platform, the two-drug combo consists of a cancer therapy and an anti-parasitic agent. 

Both the therapies have previously obtained approval from the US Food and Drug Administration (FDA).

Intended to address the viral load, as well as the inflammatory aspects of Covid-19, the treatment demonstrated to reduce SARS-CoV-2 viral load in cell and animal studies.  

It was also found to have no negative side effects.

To commence the trial, the company will seek necessary UK Ethics Committee approval and identify appropriate study centres. 

The trial is anticipated to enrol 150 subjects with mild-to-moderate Covid-19 in the UK trial.

Skymount Medical chief medical and scientific officer Dr Kishor Wasan said: “There are currently limited approved oral medication options to alleviate Covid-19 symptoms in adult patients who are not hospitalised, and the drug combination or single drug would be administered at the first sign of infection, reducing the amount and duration of symptoms, and allowing patients to avoid hospitalisation. 

“With our drug combination already in a human pilot study in the United States, we are pleased to expand the reach of this combination therapy internationally.”

Utilising various crucial components, the DeepDrug platform offers a compound and formula generation expertise that significantly lowers the time and expenses linked to standard drug discovery.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU